FMP
Clearside Biomedical, Inc.
CLSD
NASDAQ
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
0.872 USD
-0.0577 (-6.61%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
sector
Healthcare
industry
Biotechnology
website
https://www.clearsidebio.comexchange
NASDAQ
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated i...
CIK
0001539029
ISIN
US1850631045
CUSIP
185063104
Address
900 North Point Parkway
Phone
678 270 3631
Country
US
Employee
30
IPO Date
Jun 2, 2016
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CLSD Financial Summary
CIK
0001539029
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
185063104
ISIN
US1850631045
Country
US
Price
0.87
Beta
2.33
Volume Avg.
720.39k
Market Cap
66.16M
Shares
-
52-Week
0.801-2.12
DCF
-0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.94
P/B
-
Website
https://www.clearsidebio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CLSD News
It looks like there's no news available.
